RBC Capital lowers Tesla stock price target to $475 on capex concerns

RBC Capital cut its Tesla price target slightly to $475 from $480 but kept an Outperform rating, while other firms remain constructive with targets ranging from $450 to $522. Tesla’s Q1 2026 revenue, gross profit, and adjusted EBITDA all beat consensus, and FSD subscriptions rose 51% year over year, supporting the long-term growth narrative. Offsetting this, RBC flagged $5 billion in higher capex and caution around humanoid robotics, and Tesla’s valuation remains elevated at a 360 P/E.

Analysis

The incremental signal here is not the modest target revision itself, but that the market is still paying equity-like multiples for a business whose next leg of value creation is becoming increasingly capital intensive. When capex rises while near-term earnings estimates are still drifting lower, the stock’s upside is increasingly dependent on narrative execution in autonomy rather than core automotive cash generation. That makes TSLA more sensitive to milestones than to quarterly beats: a single delayed regulatory approval or a softer launch cadence can compress the multiple quickly because the implied terminal value is doing most of the work.

The bigger second-order effect is competitive. If Tesla keeps leaning into FSD, robotaxi, and robotics, it is effectively choosing to compete on software and deployed compute, which pulls capital toward data-center-like economics and away from auto-like economics. That should widen the gap versus legacy OEMs that still trade on industrial valuation frameworks, but it also raises the bar for Tesla because software narratives are punished harder when monetization timing slips. The AI-hardware acquisition adds optionality, but it also increases integration risk and could distract management from the product cadence needed to justify the autonomy premium.

The contrarian point is that consensus may be underestimating how much of the stock is now a real-options trade on regulatory and geographic expansion rather than a simple EV call. Europe and China approvals in the next 1-2 quarters could matter more than the next earnings print if they unlock an addressable market step-up; conversely, any slippage would likely hit the stock harder than a small margin miss. In other words, near-term downside is probably capped by “good enough” operating results, but upside requires a sequence of catalysts to land on schedule, which is a tougher hurdle than the current multiple implies.

Key Decisions for Investors

• Stay tactically long TSLA only on pullbacks toward the prior support area; use a 6-12 week horizon and size for event-driven volatility, not fundamentals, because the stock is trading on catalyst sequencing rather than near-term earnings durability.
• Buy TSLA call spreads into the next regulatory milestone window (EU/China approval timing) to express upside from a successful catalyst chain while limiting premium bleed if approvals slip by a quarter.
• Pair trade: long TSLA / short a basket of legacy OEMs with limited software optionality over the next 3-6 months; the relative trade works if autonomy remains the main source of multiple expansion and capital intensity doesn’t trigger derating.
• Trim into strength if TSLA approaches the upper end of sell-side target dispersion without a confirmed regulatory or product milestone; at that point the risk/reward shifts from asymmetry to story dependency.
• For more defensive exposure, replace outright equity with a collar or call spread structure; this preserves upside to autonomy headlines while protecting against a sharp multiple reset if capex and earnings revisions continue to diverge.